Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (252)
  2. Journal Article (103)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (4)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (381)
  2. Department of Medicine (381)
  3. Hematologic Malignancies Research (381)
  4. Hematologic Malignancies, Division of (381)
  5. Myeloma (381)
  6. Survivorship Research (225)

More Groups

People
  1. Hani Hassoun (202)
  2. Heather Landau (187)
  3. Sergio Giralt (185)
  4. David Chung (175)
  5. Neha Korde (174)
  6. Sham Mailankody (170)

More People

Years
  1. 2025 (12)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (41)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (12)

More Publications

Publishers
  1. American Society of Hematology (152)
  2. Elsevier Inc. (79)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (26)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (381)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Extreme body mass index and survival in newly diagnosed multiple myeloma patients
    Correspondence

    Shah, U. A.; Whiting, K.; Devlin, S.; Ershler, R.; Kanapuru, B.; Lee, D. J.; Tahri, S.; Gwise, T.; Rustad, E. H.; Mailankody, S.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Chemotherapy-related mutational signatures reveal the origins of therapy-related myeloid neoplasms
    Meeting Abstract

    Diamond, B.; Ziccheddu, B.; Boyle, E. M.; Maclachlan, K.; Taylor, J.; Watts, J. M.; Lu, S. X.; Coffey, D. G.; Bolli, N.; Papaemmanuil, E.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • CARTITUDE-1: Two-year post last patient in (LPI) results from the phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Usmani, S. Z.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A.; Munshi, N. C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Plinabulin after autologous hematopoietic cell transplant to decrease duration of neutropenia and improve quality of life peri-transplant
    Meeting Abstract

    Shah, G.; Shulman, L.; Hanley, D.; Chung, D.; Datta, A.; Dhar, P.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels
    Meeting Abstract

    Shah, U.; Castro, F.; Anuraj, A.; Blaslov, J.; Adintori, P.; Derkach, A.; Pollak, M.; Maclachlan, K.; Mailankody, S.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen
    Meeting Abstract

    Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: A retrospective study of 34 patients highlighting the need for consensus criteria
    Meeting Abstract

    Pianko, M. J.; Tiutan, T.; Derkach, A.; Jaffer-Sathick, I.; Rossi, A.; Salvatore, S.; Landau, H.; Lahoud, O.; Korde, N.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S.; Patel, D.; Shah, U.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Cevostamab is efficacious and well tolerated in patients aged < 65 and ≥65 years with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Krishnan, A.; Cohen, A.; Trudel, S.; Spencer, A.; Lesokhin, A.; Wong, C.; Choeurng, V.; Cooper, J.; Sumiyoshi, T.; Goodman, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save